Nano24med

Executive Summary

Nano24med is a clinical-stage Israeli biotech pioneering exosome-based immunomodulators to address hyper-inflammatory conditions, with its lead candidate EXO-CD24 targeting acute respiratory distress syndrome (ARDS). The inhaled therapy delivers CD24-enriched exosomes directly to the lungs to dampen cytokine storms, offering a potentially safer alternative to corticosteroids. Founded in 2020, the company has advanced EXO-CD24 into Phase 2 clinical trials, leveraging a novel platform that harnesses the natural anti-inflammatory properties of CD24. The approach has garnered interest due to its potential to treat not only ARDS but also other inflammatory diseases, though clinical validation remains ongoing. With a lean team of 10-50, Nano24med is positioned in the competitive landscape of respiratory and critical care therapeutics, relying on strategic partnerships and future funding to advance its pipeline.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Topline Data Readout for EXO-CD24 in ARDS35% success
• Q2 2027FDA or EMA Orphan Drug Designation or Fast Track60% success
• Q4 2026Licensing or Co-Development Partnership in Major Market40% success